Epigral Q1 PAT Up 25%, Board Approves ₹600 Crore Epoxy Resin Capex

27 July 2026

Epigral Ltd.

Q1FY27 revenue +15% YoY to ₹709cr, PAT +25% to ₹99cr, EBITDA margin 25%. Board approved ₹600cr capex for Epoxy Resin & Formulations (125ktpa) and Multi-Purpose Plant, commissioning H2FY28, leveraging internal raw material integration.